Latest Medical statistics Stories
Rigel Reiterates Clinical Focus on Fostamatinib for ITP and IgA Nephropathy SOUTH SAN FRANCISCO, Calif., Aug. 13, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.
Important New Variable Covered. Threshold for Meeting Primary Endpoint Lowered. BETHESDA, Md., Aug.
Published since 2006, the Orange Paper gives detailed snapshot of clinical trials in Russia. Moscow, Russia (PRWEB) August 06, 2014 Synergy Research
ALBANY, New York, July 21, 2014 /PRNewswire/ -- According to a new market report published by Transparency Market Research "E-Clinical Solution Software Market- Global
LONDON, June 23, 2014 /PRNewswire/ -- Highlights: - Creation of an international CRO with complete service offering from Phase I
Aspire IRB and Midlands IRB become part of the WCG family, further expanding its geographic and program reach PRINCETON, N.J., June 16, 2014 /PRNewswire/ -- The WIRB-Copernicus Group
PHILADELPHIA, June 16, 2014 /PRNewswire/ -- TransCelerate BioPharma Inc.
SANTA ROSA, Calif., June 4, 2014 /PRNewswire/ -- Ruthigen, Inc., (NASDAQ: RTGN), a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics
VIENNA, June 4, 2014 /PRNewswire/ -- AFFiRiS announced today the results of a phase II study in Alzheimer patients. AFFiRiS' proprietary compound AD04 is the first drug
- The parings of haberdine; also, any kind of fragments.